- Home
- COHN vs NERV Comparison
COHN vs NERV Comparison
Compare COHN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHN
- NERV
- Stock Information
- Founded
- COHN 1999
- NERV 2007
- Country
- COHN United States
- NERV United States
- Employees
- COHN N/A
- NERV N/A
- Industry
- COHN Investment Bankers/Brokers/Service
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- COHN Finance
- NERV Health Care
- Exchange
- COHN Nasdaq
- NERV Nasdaq
- Market Cap
- COHN 16.3M
- NERV 18.3M
- IPO Year
- COHN N/A
- NERV 2014
- Fundamental
- Price
- COHN $10.20
- NERV $2.29
- Analyst Decision
- COHN
- NERV Hold
- Analyst Count
- COHN 0
- NERV 1
- Target Price
- COHN N/A
- NERV $5.00
- AVG Volume (30 Days)
- COHN 31.2K
- NERV 24.1K
- Earning Date
- COHN 11-04-2024
- NERV 11-05-2024
- Dividend Yield
- COHN 9.80%
- NERV N/A
- EPS Growth
- COHN N/A
- NERV N/A
- EPS
- COHN 2.35
- NERV N/A
- Revenue
- COHN $89,555,000.00
- NERV N/A
- Revenue This Year
- COHN N/A
- NERV N/A
- Revenue Next Year
- COHN N/A
- NERV N/A
- P/E Ratio
- COHN $4.35
- NERV N/A
- Revenue Growth
- COHN 63.18
- NERV N/A
- 52 Week Low
- COHN $6.04
- NERV $2.07
- 52 Week High
- COHN $12.82
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- COHN 59.54
- NERV 45.73
- Support Level
- COHN $9.41
- NERV $2.08
- Resistance Level
- COHN $11.52
- NERV $2.35
- Average True Range (ATR)
- COHN 0.53
- NERV 0.11
- MACD
- COHN -0.00
- NERV 0.00
- Stochastic Oscillator
- COHN 37.44
- NERV 56.27
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.